发明名称 |
PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling |
摘要 |
The present invention demonstrates that chronic active BCR signaling through CD79A/B confers a strong dependence on downstream PKCb kinase signaling. Hence, provided herein is a method for inhibiting the growth of B-cell lymphoma having chronic active B-cell-receptor signaling, or inhibiting the growth of cancers with molecular lesions that lead to chronic active BCR signaling, by administering to a patient in need of such treatment a therapeutically effective amount of a PKC inhibitor or a use of a PKC inhibitor to inhibit the growth of B-cell lymphoma having chronic active B-cell-receptor signaling or to inhibit the growth of cancers with molecular lesions that lead to chronic active BCR signaling. |
申请公布号 |
AU2011234644(B2) |
申请公布日期 |
2014.07.17 |
申请号 |
AU20110234644 |
申请日期 |
2011.03.28 |
申请人 |
NOVARTIS AG |
发明人 |
SCHULER, WALTER;STEGMEIER, FRANK P.;WARMUTH, MARKUS |
分类号 |
A61K31/00;A61K31/404;A61K31/407;A61K31/436;A61K31/499;A61K31/517;A61K45/06;A61P35/00 |
主分类号 |
A61K31/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|